AzTrials
AzTrials

Pain, PostoperativePhase 2/3CATHEPATNCT03238430

Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia .

A Phase 2/3 study testing intrathecal morphine, Morphine PCA and Ropivacaine infiltration in people with Pain, Postoperative, run by University Hospital, Lille at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Analgesia in liver surgery is a challenge, postoperative coagulopathy risk raises fears an epidural haematoma formation following the epidural analgesia, "gold standard" in major abdominal surgery. The spinal analgesia and/or continuous wound infiltration of local anesthetics constitute so an alternative. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pain, Postoperative
What is being tested?
intrathecal morphine, Morphine PCA and Ropivacaine infiltration
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
186 participants
Where
1 siteFrance
Study dates
20 May 2015to 25 May 2019
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Surgery of hepatic resection by first under costal.
  • Patient classified ASA 1 to 3.
  • Information, signed and informed consent

Who cannot join

  • Patients classified ASA 4 or 5.
  • Allergy or intolerance to any of the products used in the protocol.
  • Emergency surgery, palliative surgery, surgical recovery.
  • History of chronic pain requiring the regular use of analgesics, especially opioids.
  • History of drug misuse.
  • Inability to understand and / or use the patient's self-controlled morphine pump.
Show all 9Show fewer
  • Known history of psychiatric disorders or current psychotropic treatment (excluding benzodiazepine monotherapy)
  • Additive behavior with respect to alcohol or non-weaned psychodysleptic substances
  • Pregnant Woman or Breastfeeding

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHRU , Hôpital Claude Huriez

    Lille

Other trials in France

About this study

Analgesia in liver surgery is a challenge, postoperative coagulopathy risk raises fears an epidural haematoma formation following the epidural analgesia, "gold standard" in major abdominal surgery. The spinal analgesia and/or continuous wound infiltration of local anesthetics constitute so an alternative.

The study will compare the continuous infiltration of local anesthetics and rachianalgesia in terms of decreased postoperative morphine consumption and incidences of chronic postoperative pain at 3 and 6 months after hepatic surgery compared to the control group.

Being tested
intrathecal morphine, Morphine PCA, Ropivacaine infiltration
Keywords
Intrathecal morphine, continuous wound infiltration
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • intrathecal morphineDrug

    A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.

  • Morphine PCADrug

    a postoperative Morphine PCA

  • Ropivacaine infiltrationDrug

    Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml

Study groups in NCT03238430
Study groupRoleWhat they receive
Ropivacaine infiltrationExperimentalContinuous infiltration of local anesthetics + PCA morphine.
Receives: Drug: intrathecal morphine; Drug: Morphine PCA
intrathecal morphineExperimentalRachianalgesia + PCA morphine
Receives: Drug: Morphine PCA; Drug: Ropivacaine infiltration
morphine PCAActive comparatorPCA morphine alone
Receives: Drug: Morphine PCA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Morphine Consumption

    Morphine consumption is measured all 3 hours during the first 24 hours post operative

    Measured: During the first 24 hours post operative

Secondary outcomes (20)
  1. Morphine Consumption

    Morphine consumption is measured all 3 hours during the 48 hours post operative

    Measured: During the 48 hours post operative

  2. Evaluation of postoperative pain intensity at rest

    The postoperative pain intensity is measured by Visual Analog Scale at rest

    Measured: All 3 hours during the 48 postoperative hours

  3. Evaluation of postoperative pain intensity after activity

    The postoperative pain intensity is measured by Visual Analog Scale after activity

    Measured: All 3 hours during the 48 postoperative hours

  4. Electric nociception threshold measured by PainMatcher

    The Electric nociception threshold is measured by PainMatcher (CefarCompex®)

    Measured: At the exit of Post Anesthesia Care Unit

  5. Electric nociception threshold measured by PainMatcher

    The Electric nociception threshold is measured by PainMatcher (CefarCompex®)

    Measured: At 24 hours post operative

  6. Electric nociception threshold measured by PainMatcher

    The Electric nociception threshold is measured by PainMatcher (CefarCompex®)

    Measured: At 48 hours post operative

  7. Number of patient with a chronic pain after liver surgery, measured by Questionnaire Douleur de Saint-Antoine (QDSA)

    Evaluation with validated score for chronic and neuropathic pains (QDSA is the French translation of the MPQ "Mac Gill bread questionary")

    Measured: At 3 months after surgery

  8. Number of patient with a chronic pain after liver surgery, measured by Questionnaire Douleur de Saint-Antoine (QDSA)

    Evaluation with validated score for chronic and neuropathic pains (QDSA is the French translation of the MPQ "Mac Gill bread questionary")

    Measured: At 6 months after surgery

  9. Number of patient with a chronic pain after liver surgery, measured by Neuropathic Pain Symptom Inventory (NPSI)

    Evaluation with validated score for chronic and neuropathic pains (NPSI)

    Measured: At 3 months after surgery

  10. Number of patient with a chronic pain after liver surgery, measured by Neuropathic Pain Symptom Inventory (NPSI),

    Evaluation with validated score for chronic and neuropathic pains (NPSI)

    Measured: At 6 months after surgery

  11. Number of patient with a chronic pain after liver surgery, measured by Neuropathic pain diagnostic questionnaire (DN2),

    Evaluation with validated score for chronic and neuropathic pains (DN2)

    Measured: At 3 months after surgery

  12. Number of patient with a chronic pain after liver surgery, measured by Neuropathic pain diagnostic questionnaire (DN2),

    Evaluation with validated score for chronic and neuropathic pains (DN2)

    Measured: At 6 months after surgery

  13. Area peri-incisional hyperalgesia

    The Surface of the cutaneous Area peri-incisional hyperalgesia is measured by Von frey's Filament.

    Measured: At 48 hours post operative

  14. Number of nausea and/or vomiting episodes

    Measured by collection of episodes of nausea and/or vomiting and consumption of anti-emetics

    Measured: At 24 hours after surgery

  15. Number of nausea and/or vomiting episodes

    Measured by collection of episodes of nausea and/or vomiting and consumption of anti-emetics

    Measured: At 48 hours after surgery

  16. Number of nausea and/or vomiting episodes

    Measured by collection of episodes of nausea and/or vomiting and consumption of anti-emetics

    Measured: At 72 hours after surgery

  17. Number of patient with side effect of morphine consumption

    Respiratory Depression, Urinary retention, Prurit

    Measured: Up to 72 hours after surgery

  18. Time physiological function recovery

    Nasogastric tube withdrawal time, Transit recovery, Ability to drink, to eat, to urinate, to walk

    Measured: Up to the end of hospital stay, an average 10 days

  19. Length of hospital stay in intensive care unit

    Measured: Up to the end of hospital stay,an average 10 days

  20. Length of hospital stay

    Measured: Up to the end of hospital stay , an average 10 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2017
  2. Study start20 May 2015
  3. Primary completion25 May 2019
  4. Study completion25 May 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
186 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03238430
Sponsor's protocol ID
2013_48
Other IDs
2014-003317-28, 2014
Acronym
CATHEPAT
Status last verified
Aug 2020
First submitted
31 Jul 2017
Last updated
22 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Rousseleau D, Plane B, Labreuche J, Pierache A, El Amine Y, Ethgen S, Wattier JM, Cirenei C, Boleslawski E, Lebuffe G. Comparison of catheter wound infusion, intrathecal morphine, and intravenous analgesia for postoperative pain management in open liver resection: randomized clinical trial. BJS Open. 2025 Jul 1;9(4):zraf074. doi: 10.1093/bjsopen/zraf074.

    PubMed 40662757

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing intrathecal morphine, Morphine PCA and Ropivacaine infiltration in people with Pain, Postoperative, run by University Hospital, Lille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Morphine Consumption (time frame: During the first 24 hours post operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03238430, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in